Company intelligence / Profile preview
Novome Biotechnologies
South San Francisco, California, United Statesnovomebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed Phase 1 study of NOV-001 in healthy volunteers demonstrating safe colonization of the human gut with a therapeutically engineered microbe. Initiated Phase 2a study to evaluate preliminary efficacy in patients with enteric hyperoxaluria[4].
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Genetically Engineered Microbial Medicines (GEMMs)engineered cellular therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Genentech (Roche subsidiary) - multi-year research collaboration and licensing agreement signed in November 2021[2][4]
Beyond the preview
Go deeper on Novome Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novome Biotechnologies.